Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New-onset diabetes mellitus after renal transplantation: belatacept-based versus tacrolimus-based immunosuppression
2011-006162-40Phase 4Terminated
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Mar 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of belatacept in carbohydrate malabsorption, diabetes mellitus (DM) and prediabetes (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Incidence of glucose metabolism alterations (PREDAT or NODAT). Started Mar 2013; status: terminated.
02
Drugs
belatacept
03
Conditions
carbohydrate malabsorptiondiabetes mellitus (DM)prediabetes
Beyond the preview
Go deeper on 2011-006162-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006162-40.